Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited
Key Takeaways
- GLP-1 medications mimic glucagon-like peptide-1, a hormone your gut releases after meals to coordinate insulin release, gastric emptying, and appetite signaling
- The class formally includes five pure GLP-1 receptor agonists approved by the FDA: liraglutide, semaglutide, exenatide, dulaglutide, and lixisenatide (the last discontinued in the U.S. in 2023)
- Tirzepatide (Mounjaro, Zepbound) is often grouped with GLP-1 medications but is technically a dual GLP-1/GIP agonist, a separate sub-class
- Investigational drugs like retatrutide (triple agonist) extend the mechanism further by adding glucagon receptor activation, but are not FDA-approved as of May 2026
- The mechanism is the same hormone biology across the class; the differences are in receptor selectivity, half-life, and approved indications
Direct answer
A GLP-1 medication is a drug that activates the glucagon-like peptide-1 receptor, mimicking a hormone your intestine releases after meals. The formal class name is glucagon-like peptide-1 receptor agonist, often abbreviated GLP-1 RA. These medications lower blood sugar in type 2 diabetes and reduce body weight in obesity by acting on receptors in the pancreas, stomach, intestine, and several brain regions that regulate appetite.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The hormone behind the drug class
- How receptor agonism works in plain terms
- Every FDA-approved GLP-1 medication, by brand and by molecule
- Dual agonists: where tirzepatide fits
- The mechanism in three locations: pancreas, gut, brain
- Why the class works for both diabetes and obesity
- How the medications differ within the class
- Side effects shared across the class
- Where compounded versions fit, and where they don't
- The investigational pipeline beyond GLP-1
- Contrary view: limits of the GLP-1 framework
- Decision framework
- FAQ
- Sources
The hormone behind the drug class
Glucagon-like peptide-1 is a 30 or 31 amino acid peptide hormone produced by L-cells lining your distal small intestine and colon. When you eat, especially when carbohydrates or fats reach these cells, they release GLP-1 into the bloodstream within minutes. Levels rise sharply during a meal and fall back to baseline within an hour or two.
The hormone has a remarkably short half-life in its natural form. Native GLP-1 is broken down by an enzyme called DPP-4 (dipeptidyl peptidase-4) within roughly two minutes of release. That short half-life is why natural GLP-1 can't be used as a drug. Every approved GLP-1 medication is a modified version of the molecule that resists DPP-4 degradation, allowing it to circulate long enough to produce a sustained effect.
The native hormone does several things. It stimulates insulin release from pancreatic beta cells, but only when blood sugar is elevated, which is why GLP-1 medications rarely cause hypoglycemia on their own. It suppresses glucagon release from alpha cells, reducing the liver's release of stored glucose. It slows the rate at which the stomach empties food into the small intestine. And it acts on the brain to reduce appetite and increase satiety after meals.
People with type 2 diabetes have blunted GLP-1 responses to meals. People with obesity also show reduced postprandial GLP-1, though the relationship is less clear. The drug class works by amplifying and prolonging this hormonal signal far beyond what the natural hormone can achieve.
How receptor agonism works in plain terms
A receptor is a protein on the surface of a cell. When the right molecule binds to it, the cell changes its behavior. The GLP-1 receptor is found on beta cells in the pancreas, neurons in the hypothalamus and brainstem, and cells throughout the gut.
An agonist is a molecule that binds to a receptor and activates it. The natural agonist is the GLP-1 hormone itself. A receptor agonist drug is a synthetic or modified molecule designed to bind the same receptor and produce the same downstream effects.
Semaglutide is about 94 percent identical to native human GLP-1. The modifications are small, but they make the molecule resistant to DPP-4, allow it to bind to albumin in the blood (which extends its circulating half-life to about a week), and let it cross the blood-brain barrier where it acts on appetite centers.
Liraglutide is 97 percent identical to native GLP-1, with a fatty acid chain attached that lets it bind to albumin. Its half-life is about 13 hours, requiring daily injection.
Exenatide is structurally different. It is based on exendin-4, a peptide found in the saliva of the Gila monster, a venomous lizard native to the southwestern United States. Exendin-4 is about 53 percent identical to human GLP-1 but happens to activate the same receptor while being naturally resistant to DPP-4. Exenatide was the first GLP-1 medication approved by the FDA, in April 2005.
Dulaglutide is a fusion protein, with two modified GLP-1 sequences attached to an antibody fragment. The antibody portion gives it a long half-life, allowing once-weekly dosing.
Every FDA-approved GLP-1 medication, by brand and by molecule
As of May 2026, the following pure GLP-1 receptor agonists are or have been approved by the FDA:
| Generic name | Brand name(s) | Indication | Dosing | Approval year |
|---|---|---|---|---|
| Exenatide (immediate release) | Byetta | Type 2 diabetes | Twice-daily injection | 2005 |
| Exenatide (extended release) | Bydureon, Bydureon BCise | Type 2 diabetes | Once-weekly injection | 2012 |
| Liraglutide | Victoza | Type 2 diabetes | Daily injection | 2010 |
| Liraglutide (higher dose) | Saxenda | Chronic weight management | Daily injection | 2014 |
| Lixisenatide | Adlyxin | Type 2 diabetes (discontinued U.S. 2023) | Daily injection | 2016 |
| Dulaglutide | Trulicity | Type 2 diabetes | Once-weekly injection | 2014 |
| Semaglutide (injectable) | Ozempic | Type 2 diabetes | Once-weekly injection | 2017 |
| Semaglutide (oral) | Rybelsus | Type 2 diabetes | Daily tablet | 2019 |
| Semaglutide (higher dose) | Wegovy | Chronic weight management | Once-weekly injection | 2021 |
Three molecules dominate current prescribing: liraglutide, semaglutide, and exenatide. Of these, semaglutide accounts for the majority of new prescriptions due to weekly dosing and superior weight outcomes compared with liraglutide.
Dual agonists: where tirzepatide fits
Tirzepatide, marketed as Mounjaro for type 2 diabetes (approved May 2022) and Zepbound for obesity (approved November 2023), activates two receptors instead of one. It binds the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide receptor), both of which are part of the incretin system.
This matters in two ways. First, the weight-loss effect is larger than pure GLP-1 RAs. SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine 2022) reported mean weight loss of about 22.5 percent of body weight on tirzepatide 15 mg over 72 weeks, compared with about 14.9 percent on semaglutide 2.4 mg in STEP 1.
Second, the side-effect profile and dosing are similar to pure GLP-1 RAs, but the molecule is not a GLP-1 medication in the strict sense. Tirzepatide is classified as a dual GIP and GLP-1 receptor agonist, sometimes called a "twincretin." When people ask if Mounjaro or Zepbound is a GLP-1, the most accurate answer is "yes and no." It activates the GLP-1 receptor as part of its mechanism, but it is not pure GLP-1 like Ozempic or Wegovy.
In clinical conversation, most providers group tirzepatide with GLP-1 medications because the patient experience and supply chain overlap. In pharmacology textbooks, it occupies its own row.
The mechanism in three locations: pancreas, gut, brain
GLP-1 receptors are expressed in many tissues, but three locations matter most clinically.
In the pancreas. Beta cells release insulin in response to GLP-1 activation, but only when blood glucose is elevated. This glucose-dependence is why GLP-1 medications rarely cause hypoglycemia unless combined with insulin or sulfonylureas. Alpha cells reduce glucagon secretion, which lowers the liver's hepatic glucose output. Together, these effects reduce both fasting and postprandial glucose.
In the gut. GLP-1 slows gastric emptying. Food remains in the stomach longer, blunting the post-meal glucose spike and prolonging the sense of fullness. Slowed gastric emptying is also the main mechanism behind nausea, which is why nausea is the most common side effect during dose escalation.
In the brain. GLP-1 receptors in the arcuate nucleus of the hypothalamus, the area postrema in the brainstem, and several reward-related regions reduce appetite. Patients typically describe this as a quieting of "food noise," reduced cravings, and earlier satiety during meals. The behavioral effect explains most of the weight loss; the medication works less by burning calories and more by reducing intake.
The brain mechanism is why GLP-1 medications work for weight loss even in people without diabetes. The hormone signals satiety regardless of glucose status.
Why the class works for both diabetes and obesity
The dual application makes sense once you understand the hormone. GLP-1 was discovered in the context of insulin regulation. The early drugs (exenatide, liraglutide, dulaglutide) were approved for diabetes. Weight loss was first noticed as a side effect.
As doses increased, the weight-loss effect became larger. Liraglutide for diabetes (Victoza) is dosed up to 1.8 mg daily. Liraglutide for obesity (Saxenda) is the same molecule at 3.0 mg daily. Semaglutide for diabetes (Ozempic) is dosed up to 2.0 mg weekly. Semaglutide for obesity (Wegovy) is the same molecule at 2.4 mg weekly.
The cardiovascular effects added another layer. The LEADER trial (Marso et al., New England Journal of Medicine 2016) for liraglutide and the SELECT trial (Lincoff et al., New England Journal of Medicine 2023) for semaglutide showed reductions in major adverse cardiovascular events independent of weight loss. The class now has cardiovascular indications in some patients.
How the medications differ within the class
The drugs share a mechanism but differ in practical ways:
- Half-life. Exenatide IR (hours), liraglutide (~13 hours), dulaglutide and semaglutide (about 5 to 7 days), exenatide ER (about 2 weeks at steady state).
- Dosing route. Most are subcutaneous injection. Rybelsus is the only oral GLP-1, taken daily on an empty stomach with a small amount of water.
- Weight-loss magnitude. Semaglutide produces more weight loss than liraglutide head-to-head (STEP 8 trial, Rubino et al., JAMA 2022). Tirzepatide produces more than semaglutide (SURMOUNT-5 head-to-head data).
- Cardiovascular evidence. Liraglutide, semaglutide, and dulaglutide have positive cardiovascular outcome trials. Exenatide and lixisenatide do not.
- Approved indication. Some products are approved only for diabetes (Ozempic, Victoza, Trulicity), some only for weight management (Wegovy, Saxenda, Zepbound), and some for both populations as separate products.
Side effects shared across the class
Gastrointestinal side effects are the defining feature of the class. Nausea is reported by roughly 40 to 60 percent of patients during titration in trials, though most cases are mild to moderate. Vomiting, diarrhea, constipation, abdominal pain, and burping are common. Most GI effects improve after the first 8 to 12 weeks.
Less common but serious effects include acute pancreatitis (rate roughly 0.2 percent per year in trials), gallbladder disease, and acute kidney injury, usually from dehydration secondary to vomiting. There is a boxed warning for medullary thyroid carcinoma based on rodent data, with a contraindication in patients with personal or family history of MEN2 syndrome.
Other reported effects include hair loss (likely secondary to rapid weight loss), increased heart rate, injection-site reactions, and rare cases of suicidal ideation that triggered an FDA review in 2024. The review found no causal signal based on the available data.
Where compounded versions fit, and where they don't
Compounded semaglutide and compounded tirzepatide became widely available in the United States during the 2022 to 2024 brand-drug shortage. A 503A compounding pharmacy can prepare a custom medication in response to an individual prescription when an FDA-approved drug is on the FDA shortage list or when a specific patient need cannot be met by the commercial product.
Compounded versions use the same active pharmaceutical ingredient (semaglutide or tirzepatide) but are not FDA-approved. They have not undergone the FDA's purity, potency, and stability review. They are not interchangeable with the brand drugs. Patients are not buying Ozempic or Mounjaro when they buy compounded semaglutide or compounded tirzepatide; they are buying a different product based on the same molecule.
The compounded market shrank significantly after the FDA removed semaglutide from the shortage list in February 2025 and tirzepatide in October 2024. Compounding under shortage rules became more restricted. As of May 2026, compounding continues under personalized prescribing rules but at lower volumes than during 2023.
The investigational pipeline beyond GLP-1
The drug class is expanding in three directions:
Triple agonists. Retatrutide, developed by Eli Lilly, activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Phase 2 data (Jastreboff et al., New England Journal of Medicine 2023) reported about 24 percent weight loss at 48 weeks on the highest dose. Phase 3 trials are ongoing. Retatrutide is investigational and not FDA-approved. FormBlends does not sell or supply retatrutide.
Oral small molecules. Orforglipron, also from Lilly, is an oral non-peptide GLP-1 RA. Unlike Rybelsus, it does not require fasting administration. Phase 3 data are emerging. Danuglipron, from Pfizer, was discontinued in 2025 due to liver enzyme abnormalities. Orforglipron and danuglipron are investigational; FormBlends does not sell or supply them.
Combination products. Cagrisema combines semaglutide with cagrilintide, an amylin analog. Mazdutide and survodutide are GLP-1/glucagon dual agonists in development. All are investigational. FormBlends does not sell or supply cagrisema, cagrilintide, mazdutide, or survodutide.
Contrary view: limits of the GLP-1 framework
The GLP-1 framework explains a lot, but it has limits.
First, the class label hides real differences in efficacy. Treating "GLP-1 medications" as interchangeable understates the gap between exenatide (about 3 to 5 percent weight loss in older trials) and semaglutide (about 14.9 percent in STEP 1). Patients sometimes assume they will get Wegovy-level outcomes from any GLP-1, which sets up disappointment.
Second, the mechanism is more complex than "appetite suppression." GLP-1 receptors in the heart, kidneys, and immune cells contribute to effects beyond glucose and weight. The cardiovascular benefit in SELECT (Lincoff et al., New England Journal of Medicine 2023) appeared earlier than predicted by weight loss alone, suggesting direct cardiovascular effects.
Third, the framework focuses on receptor agonism as the only mechanism. Other appetite-regulating pathways (amylin, leptin, ghrelin, cannabinoid) have produced approved drugs and may produce more. GLP-1 is one tool, not the answer to all weight regulation.
Fourth, the label "GLP-1" risks shorthand failure. When patients ask "is Mounjaro a GLP-1," the casual yes obscures the GIP component. The dual agonist mechanism may explain why tirzepatide produces more weight loss; treating it as just another GLP-1 may underestimate it.
Decision framework
If you have type 2 diabetes:
- Pure GLP-1 RAs (Ozempic, Trulicity, Victoza) are first-line in many guidelines, especially with cardiovascular risk factors.
- Tirzepatide (Mounjaro) is now widely used and produces stronger A1C reductions head-to-head.
- The choice depends on insurance coverage, dosing preference, and weight-loss goals.
If you have obesity without diabetes:
- FDA-approved options are Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide).
- Effect sizes differ substantially. Tirzepatide produces the largest weight loss; semaglutide is intermediate; liraglutide is smallest.
- Compounded versions exist outside the FDA-approved framework.
If you are a clinician explaining the class:
- Lead with the hormone biology: GLP-1 is a gut hormone released after meals.
- Distinguish pure GLP-1 RAs from dual agonists.
- Set expectations based on the specific drug, not the class label.
If you are researching the field:
- The pipeline includes triple agonists, oral small molecules, and combination products.
- Most pipeline drugs are still investigational and not FDA-approved.
- FormBlends does not sell or supply investigational drugs.
FAQ
What is a GLP-1 medication? A drug that activates the glucagon-like peptide-1 receptor, mimicking a gut hormone released after meals. The formal class name is glucagon-like peptide-1 receptor agonist (GLP-1 RA). These medications lower blood glucose, slow gastric emptying, and reduce appetite.
What does GLP-1 stand for? Glucagon-like peptide-1. It is a peptide hormone produced by L-cells in the small intestine after food intake.
Which medications are FDA-approved GLP-1 receptor agonists? Liraglutide (Victoza, Saxenda), semaglutide (Ozempic, Wegovy, Rybelsus), exenatide (Byetta, Bydureon), dulaglutide (Trulicity), and lixisenatide (Adlyxin, now discontinued in the U.S.).
Are Mounjaro and Zepbound GLP-1 medications? Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates the GLP-1 receptor as part of its mechanism but is not a pure GLP-1 RA. Most clinicians group it with the class for practical purposes.
How do GLP-1 medications cause weight loss? They reduce appetite via brain receptors, slow gastric emptying so meals last longer, and increase satiety. Patients typically eat 20 to 30 percent less without conscious restriction.
What is the difference between a GLP-1 and an incretin mimetic? Incretin is the broader category. GLP-1 RAs are a subset that target only the GLP-1 receptor. Dual agonists like tirzepatide are also incretin mimetics but not pure GLP-1 RAs.
What are the side effects of GLP-1 medications? Nausea, vomiting, diarrhea, constipation, and abdominal pain are most common. Rare serious effects include pancreatitis, gallbladder disease, and contraindication in MEN2 syndrome.
Are compounded GLP-1 medications real GLP-1 medications? Compounded semaglutide and tirzepatide use the same active ingredients as the brand drugs but are not FDA-approved. They are prepared by 503A pharmacies under individual prescriptions and are not interchangeable with brand-name products.
Who invented GLP-1 medications? Joel Habener and Daniel Drucker characterized the hormone in the 1980s. John Eng identified exendin-4 in Gila monster venom, leading to exenatide. Lotte Bjerre Knudsen at Novo Nordisk led the development of liraglutide and semaglutide.
Why is the half-life of GLP-1 medications so different from natural GLP-1? Natural GLP-1 is destroyed by the DPP-4 enzyme within about two minutes. The synthetic drugs are engineered to resist DPP-4 and to bind to albumin in the blood, extending half-lives from minutes to days.
Do GLP-1 medications cure diabetes or obesity? No. They are chronic treatments. Stopping the medication typically leads to regain of weight and worsening of glucose control over time, as shown in the STEP 4 trial and Wegovy withdrawal data.
What is the next-generation GLP-1 medication? Retatrutide is the most advanced triple agonist in development (GLP-1, GIP, glucagon). Orforglipron is an oral small-molecule GLP-1 RA in late-stage trials. Both are investigational and not FDA-approved.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine. 2016.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). New England Journal of Medicine. 2023.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
- Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007.
- Knudsen LB et al. Liraglutide: The Therapeutic Promise from Animal Models. International Journal of Clinical Practice. 2010.
- FDA Prescribing Information. Wegovy (semaglutide). Updated 2024.
- FDA Prescribing Information. Zepbound (tirzepatide). Updated 2024.
- FDA Prescribing Information. Ozempic (semaglutide). Updated 2024.
- Eng J et al. Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom. Journal of Biological Chemistry. 1992.
- Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022.
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with independent licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication. Clinical decisions are made by the prescribing provider, not the platform.
Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are prepared by state-licensed 503A pharmacies in response to individual prescriptions. They are not FDA-approved. They have not undergone the FDA's purity, potency, and stability review and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
Results Disclaimer. Weight-loss outcomes vary by individual. Trial averages reflect controlled clinical conditions and may not match real-world experience. Outcomes depend on adherence, diet, exercise, and individual response.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly. Byetta and Bydureon are registered trademarks of AstraZeneca. Victoza and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by these manufacturers.